Modern management of epilepsy: A practical approach

Epilepsy and Behavior

Volumn 12, Issue 4, 2008, Pages 501-539

  Elger, Christian E ^a   Schmidt, Dieter ^b  

^a UNIVERSITY OF BONN   (Germany)

^b Epilepsy Research Group   (Germany)

Author keywords

Antiepileptic drugs; Drug treatment; Epilepsy; Epilepsy management; Epilepsy surgery; Nonepileptic seizures

Indexed keywords

ACETAZOLAMIDE; ANTICONVULSIVE AGENT; CARBAMAZEPINE; CLONAZEPAM; CLORAZEPATE; DIAZEPAM; ETHOSUXIMIDE; ETHOTOIN; ETIRACETAM; FELBAMATE; FOSPHENYTOIN SODIUM; GABAPENTIN; LAMOTRIGINE; LORAZEPAM; MEPHENYTOIN; MESUXIMIDE; MIDAZOLAM; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PREGABALIN; PRIMIDONE; SEROTONIN UPTAKE INHIBITOR; TIAGABINE; TOPIRAMATE; TRIMETHADIONE; UNINDEXED DRUG; VALPROIC ACID; VIGABATRIN; ZONISAMIDE;

ABSENCE; ACCIDENTAL INJURY; ADD ON THERAPY; ADJUVANT THERAPY; ALTERNATIVE MEDICINE; ANOREXIA; ANTICOAGULATION; ANTICONVULSANT ACTIVITY; ANXIETY; APHASIA; APLASTIC ANEMIA; BEDTIME DOSAGE; BENIGN CHILDHOOD EPILEPSY; BODY WEIGHT DISORDER; BONE DISEASE; BRAIN DEPTH STIMULATION; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; COGNITIVE DEFECT; COMBINATION CHEMOTHERAPY; COMORBIDITY; DEPRESSION; DIAGNOSTIC ERROR; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DOSE KIDNEY FUNCTION RELATION; DOSE LIVER FUNCTION RELATION; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG INHIBITION; DRUG MEGADOSE; DRUG METABOLISM; DRUG MONITORING; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EARLY DIAGNOSIS; ELECTROENCEPHALOGRAPHY; ENDOCRINE FUNCTION; EPILEPSY; EPILEPTIC STATE; EPILEPTOGENESIS; EVENING DOSAGE; EVIDENCE BASED MEDICINE; FOCAL EPILEPSY; FRONTAL LOBE EPILEPSY; GENERALIZED EPILEPSY; GENETIC VARIABILITY; HIGH RISK POPULATION; HUMAN; HYPONATREMIA; INSULIN METABOLISM; IRRITABILITY; KETOGENIC DIET; LIVER FAILURE; LOW DRUG DOSE; MENOPAUSE; MENTAL DISEASE; MONOTHERAPY; MORTALITY; MYOCLONUS; MYOCLONUS SEIZURE; NEPHROLITHIASIS; NEUROIMAGING; NEUROPHYSIOLOGY; NEUROSURGERY; NEUROTOXICITY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; ONSET AGE; OSTEOMALACIA; OSTEOPENIA; OSTEOPOROSIS; OVARY POLYCYSTIC DISEASE; PARASOMNIA; PATHOPHYSIOLOGY; PATIENT CARE; PATIENT COMPLIANCE; PERIPHERAL EDEMA; PHARMACOGENETICS; PREGNANT WOMAN; PROGNOSIS; PSYCHOGENESIS; PSYCHOSIS; RESTLESS LEGS SYNDROME; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT; SOMNOLENCE; SUICIDAL IDEATION; SYNCOPE; TEMPORAL LOBE EPILEPSY; TERATOGENICITY; THERAPEUTIC ERROR; TREMOR; VAGUS NERVE STIMULATION; VISUAL FIELD DEFECT; WEIGHT CHANGE; WEIGHT GAIN; WEIGHT REDUCTION;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTICONVULSANTS; CHILD; CHILD, PRESCHOOL; EPILEPSY; FEMALE; FRONTAL LOBE; HUMANS; MALE; MIDDLE AGED; NEUROSURGICAL PROCEDURES; SEIZURES; TEMPORAL LOBE;

EID: 40849139088     PISSN: 15255050     EISSN: 15255069     Source Type: Journal    
DOI: 10.1016/j.yebeh.2008.01.003     Document Type: Review

References (53)

1. In: Levy R.H., Mattson R.H., Meldrum B., and Perucca E. (Eds). Antiepileptic drugs. fifth ed. (2002), Lippincott, Williams &Wilkins, Philadelphia
2. Shorvon S. Handbook of epilepsy treatment (2000), Blackwell Science, Oxford
3. Engel J Jr, Pedley T, editors. Epilepsy: a comprehensive textbook, 2nd ed. Vols. 1-3. Philadelphia: Lippincott Williams & Wilkins; 2007.
4. Fisher R.S., van Emde B.W., Blume W., et al. Epileptic seizures and epilepsy: definitions proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE). Epilepsia 46 (2005) 470-472
5. Kwan P., and Sander J.W. The natural history of epilepsy: an epidemiological view. J Neurol Neurosurg Psychiatry 75 (2004) 1376-1381
6. Jefferys J.G. Models and mechanisms of experimental epilepsies. Epilepsia 44 Suppl. 12 (2003) 44-50
7. Duncan J.S., Sander J.W., Sisodiya S.M., and Walker M.C. Adult epilepsy. Lancet 367 (2006) 1087-1100
8. McCormick D.A., and Contreras D. On the cellular and network bases of epileptic seizures. Annu Rev Physiol 63 (2001) 815-846
9. Chang B.S., and Lowenstein D.H. Epilepsy. N Engl J Med 349 (2003) 1257-1266
10. Commission on Neuroimaging of the International League Against Epilepsy. Recommendations for neuroimaging of patients with epilepsy. Epilepsia 1997;38:1255-6.
11. Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for a revised clinical and electroencephalographic classification of epileptic seizures. Epilepsia 1981;22:489-501.
12. Smith D., Defalla B.A., and Chadwick D.W. The misdiagnosis of epilepsy and the management of refractory epilepsy in a specialist clinic. Q J Med 92 (1999) 15-23
13. Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for revised classification of epilepsies and epileptic syndromes. Epilepsia 1989;30:389-99.
14. Granger N., Convers P., Beauchet O., et al. First epileptic seizure in the elderly: electroclinical and etiological data in 341 patients. Rev Neurol (Paris) 158 (2002) 1088-1095
15. Tellez-Centano J.F., Patten S.B., Jette N., et al. Psychiatric comorbidity in epilepsy: a population-based analysis. Epilepsia 48 (2007) 2336-2344
16. Sillanpää M., and Schmidt D. Natural history of treated childhood-onset epilepsy: prospective, long-term population-based study. Brain 129 (2006) 617-624
17. Marson A., Jacoby A., Johnson A., et al. Immediate versus deferred antiepileptic drug treatment for early epilepsy and single seizures: a randomised controlled trial. Lancet 365 (2005) 2007-2013
18. Rogawski M., and Löscher W. The neurobiology of antiepileptic drugs. Nat Rev 5 (2004) 1-13
19. Patsalos P.N., and Perucca E. Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs. Lancet Neurol 2 (2003) 347-356
20. Strolin-Benedetti M. Enzyme induction and inhibition by new antiepileptic drugs: a review of human studies. Fundam Clin Pharmacol 14 (2000) 301-309
21. Alvestad S., Lydersen S., Brodtkorb, et al. Rash from antiepileptic drugs: influence by gender, age, and learning disability. Epilepsia 48 (2007) 1360-1365
22. Zaccara G., Franciotta D., and Perucca E. Idiosyncratic adverse reactions to antiepileptic drugs. Epilepsia 48 (2007) 1223-1244
23. Morrow J.I., Craig J.J., Russell, et al. Which antiepileptic drugs are safest in pregnancy?. Epilepsia 44 Suppl. 8 (2003) PO96
24. Morrow J., Russell A., Guthrie E., et al. Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. J Neurol Neurosurg Psychiatry 77 (2006) 193-198
25. French J.A., Kanner A.M., Bautista J., et al. Efficacy and tolerability of the new antiepileptic drugs: I. Treatment of new-onset epilepsy. Report of the TTA and QSS Subcommittees of the American Academy of Neurology and the American Epilepsy Society. Epilepsia 45 (2004) 401-409
26. French J.A., Kanner A.M., Bautista J., et al. Efficacy and tolerability of the new antiepileptic drugs: I. Treatment of refractory epilepsy. Report of the TTA and QSS Subcommittees of the American Academy of Neurology and the American Epilepsy Society. Epilepsia 45 (2004) 410-423
27. Marson AG, Al-Kharusi AM, Alwaidh M, et al. The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial. Lancet 2007;24;369:1016-1026.
28. Marson A.G., Al-Kharusi A.M., Alwaidh M., et al. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblended randomised controlled trial. Lancet. 369 (2007) 1000-1015
29. Kwan P., and Brodie M.J. Effectiveness of first antiepileptic drug. Epilepsia 10 (2001) 1255-1260
30. Schmidt D., and Gram L. Monotherapy versus polytherapy in epilepsy. CNS Drugs 3 (1995) 194-208
31. Hakkarainen H. Carbamazepine vs. diphenylhydantoin vs. their combination in adult epilepsy. Neurology 30 (1980) 354
32. Beghi E., Gatti G., Tonini C., et al. Adjunctive therapy versus alternative monotherapy in patients with partial epilepsy failing on a single drug: a multicentre, randomised, pragmatic controlled trial. Epilepsy Res 57 (2003) 1-13
33. Kwan P., and Brodie M.J. Early identification of refractory epilepsy. N Engl J Med 342 (2000) 314-339
34. Luciano A.L., and Shorvon S.D. Results of treatment changes in patients with apparently drug-resistant chronic epilepsy. Ann Neurol 62 (2007) 375-381
35. Callaghan B.C., Anand K., Hesdorffer D., Hauser W.A., and French J.A. Likelihood of seizure remission in an adult population with refractory epilepsy. Ann Neurol 62 (2007) 382-389
36. Hauser W.A. The natural history of drug resistant epilepsy: epidemiological considerations. In: Surgical treatment of epilepsy. Epilepsy Res Suppl. 5 (1992) 25-28
37. Berg A.T., Vickrey B.G., Testa F.M., et al. How long does it take for epilepsy to become intractable? A prospective investigation. Ann Neurol 60 (2006) 73-79
38. Schmidt D., and Löscher W. Drug resistance in epilepsy: putative neurobiologic and clinical mechanisms. Epilepsia 46 (2005) 858-877
39. Schmidt D. Single drug therapy for intractable epilepsy. J Neurol 229 (1983) 231-236
40. Rowan A.J., Ramsay R.E., Collins J.F., et al. New onset geriatric epilepsy: a randomised study of gabapentin, lamotrigine, and carbamazepine. Neurology 64 (2005) 1868-1873
41. Cramer J.A., Gordon J., Schachter S., and Devinsky O. Women with epilepsy: hormonal issues from menarche through menopause. Epilepsy Behav 11 (2007) 160-176
42. Medical Research Council Antiepileptic Drug Withdrawal Study Group. Randomised study in anti-epileptic drug withdrawal in patients in remission. Lancet. 1991;337:1175-1180.
43. Engel Jr. J., Wiebe S., French J., et al. Practice parameter: temporal lobe and localized neocortical resections for epilepsy. Report of the Quality Standards Subcommittee of the American Academy of Neurology, in Association with the American Epilepsy Society and the American Association of Neurological Surgeons. Neurology 60 (2003) 538-547
44. Kelley K., and Theodore W.H. Prognosis 30 years after temporal lobectomy. Neurology 64 (2005) 1974-1976
45. Schmidt D., and Löscher W. How effective is surgery to cure seizures in drug-resistant temporal lobe epilepsy?. Epilepsy Res 56 2/3 (2003) 85-91
46. Wiebe S., Blume W.T., Girvin J.P., et al. A randomized, controlled trial of surgery for temporal-lobe epilepsy. N Engl J Med 345 (2001) 311-318
47. Bien C.G., Schulze-Bonhage A., Soeder B.M., et al. Assessment of the long-term effects of epilepsy surgery with three different reference groups. Epilepsia 47 (2006) 1865-1869
48. Moretti-Ojemann L., and Jung M.E. Outcomes of temporal lobe epilepsy surgery. In: Miller J.W., and Silbergeld D.L. (Eds). Epilepsy surgery (2006), Taylor & Francis, New York 661-689
49. Schmidt D., Baumgartner C., and Löscher W. Seizure recurrence after planned discontinuation of antiepileptic drugs in seizure-free patients after epilepsy surgery: a review of current clinical experience. Epilepsia 45 (2004) 179-186
50. Theodore W.H., and Fisher R.S. Brain stimulation for epilepsy. Lancet Neurol 3 (2004) 111-118
51. Kossoff E.H. More fat and fewer seizures: dietary therapies for epilepsy. Lancet Neurol 3 (2004) 415-420
52. Löscher W., and Schmidt D. New horizons in the development of antiepileptic drugs: the search for new targets. A conference review. Epilepsy Res 60 (2004) 159-177
53. FDA Alert (12/12/2007). Information on carbamazepine. Available at: http://www.fda.gov/cder/drug/infopage/carbamazepine/default.htm.